Cent Nerv Syst Agents Med Chem. 2010 Mar; 10(1) : 3-15 Multiple sclerosis – established and novel therapeutic approaches. Ehling R, Berger T, Reindl M Abstract Multiple sclerosis (MS) is the most common disabling neurological disease in young adults characterized by recurrent relapses and / or progression that are attributable to multifocal inflammation, demyelination and…

2010 May;6(3):347-52 Hematopoietic stem cell transplantation in multiple sclerosis: a review of the clinical experience and a report of an international meeting. Karussis D, Vaknin-Dembinsky A Abstract Hematopoietic stem cell transplantation (HSCT), both allogeneic and autologous, has become one of the hottest topics in clinical immunology. One of the main autoimmune diseases in which HSCT…

2010 May; 6(5) : 247-55. Epub 2010 Apr 20. Stem cell transplantation in multiple sclerosis: current status and future prospects. Martino G, Franklin RJ, Van Evercooren AB, Kerr DA; Stem Cells in Multiple Sclerosis (STEMS) Consensus Group. Institute of Experimental Neurology-DIBIT 2, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy. martino.gianvito@hsr.it Abstract This article…

2010 Apr;16(4):503-10 The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Freedman MS, Bar-Or A, Atkins HL, Karussis D, Frassoni F, Lazarus H, Scolding N, Slavin S, Le Blanc K, Uccelli A Abstract Current therapies for multiple sclerosis effectively reduce inflammation, but…

Cell Adh Migr. 2010 Apr-Jun;4(2):235-40 Adult human mesenchymal cells proliferate and migrate in response to chemokines expressed in demyelination. Rice CM, Scolding NJ Abstract Systemic delivery of multipotent mesenchymal stem cells (MSC) may be of benefit in the treatment of neurological diseases, including multiple sclerosis (MS). Certainly, animal studies have demonstrated functional benefits following MSC…

2010 Mar; 9(46) : 236-42. The potential of mesenchymal stem cells for neural repair. Miller RH, Bai L, Lennon DP, Caplan AI. Centers for Stem Cells and Regenerative Medicine, Translational Neuroscience, Department of Neurosciences, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA. rhm3@case.edu Abstract Developing effective therapies for serious neurological insults remains…

2010 Feb; 45(2) : 239-48 Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Hamerschlak N, Rodrigues M, Moraes DA, Oliveira MC, Stracieri AB, Pieroni F, Barros GM, Madeira MI, SimAμes BP, Barreira AA, Brum DG, Ribeiro AA, Kutner JM, Tylberi CP, Porto PP, Santana CL, Neto JZ,…

2010 Jan;6(1):77-88 Update on the treatment options for multiple sclerosis. Niino M, Sasaki H Abstract Recent progress in the treatment of multiple sclerosis (MS) is remarkable, and the introduction of new therapies is yielding improvements in the management of MS. Furthermore, clinical trials with many different types of agents, especially selected monoclonal antibodies, have been…

2010; 51 : 237-57 Immuno-therapeutic potential of haematopoietic and mesenchymal stem cell transplantation in MS. Muraro PA, Uccelli A Abstract In the last few years there has been extraordinary progress in the field of stem cell research. Two types of stem cells populate the bone marrow: haematopoietic stem/progenitor cells (HSC) and mesenchymal stem cells (MSC).…

2009 Dec;9(12):1487-97 Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Sadan O, Melamed E, Offen D Abstract BACKGROUND: Stem-cell-based therapy is a promising new approach to handling neurodegenerative diseases. One of the most promising cellular sources is bone-marrow-derived mesenchymal stem cells (MSCs) also termed multipotent stromal cells. MSCs represent an autologous source and are abundant…